Larry Chong Park, PhD, co-founder and CEO of Naason Science, Inc., has worked in pharma/biotech drug discovery and development for the last 20 years. Prior to Naason Science, Larry, as the director of preclinical research, led and directed drug discovery campaigns from lead optimization through IND filing at CHDI Management/Foundation, Inc for 13 years. Working closely with academic and CRO partners, he has characterized several genetically engineered animal models of Huntington’s Disease and evaluated over 200+ lead compounds in vivo, some of which are now clinical candidates.
Prior to CHDI, Larry was a senior research scientist and group leader at Vertex Pharmaceuticals, Inc., Cambridge, MA, USA, where he led the in vivo pharmacology group in developing small molecule kinase inhibitors for CNS, oncology and immunology indications. Prior to Vertex, he led the CNS cell biology group to develop various HTS-Driven biochemical and cell-based screen assays at Galileo Pharmaceuticals, Inc, Santa Clara, CA, USA.
Larry received his BS in biology from UCLA, and his PhD in pharmacology and toxicology from University of California, Irvine. His postdoctoral research was in CNS metabolic diseases at the Burke Institute of Cornell Medical College.
Kyung Ho works as the team leader to manage a day-to-day operations in orchestrating and conducting preclinical studies. He is specialized in veterinary imaging and animal disease model generation from rodents to large animals. Prior to Naason Science, he worked as a DVM and study researcher in preclinical efficacy and toxicology evaluations in a national academic institution in Korea. He obtained BS in biochemistry and DVM in Korea.
Kati has 20 years experience working in different areas in marketing and advertising. She has BBA in communications and graphic designing and MSc in Economics with a focus on Innovation Management.
Our email addresses are in form firstname[at]naasonscience.com